We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
After a disastrous year in which its Alzheimer’s attempts blew up and the once biotech star David Hung jumped ship, Axovant is continuing its change-up with a new focus and a new executive.